Cervical Screening in HIV Positive Females: A Cross Sectional Study
Authors/Creators
- 1. Senior Resident, Department of Obstetrics and Gynaecology, Kamla Raja Hospital, Gajra Raja Medical College, Gwalior, Madhya Pradesh, India
- 2. Professor, Department of Obstetrics and Gynaecology, Gandhi Medical College, Bhopal, Madhya Pradesh, India
- 3. Assistant Professor, Department of Obstetrics and Gynaecology, Gandhi Medical College, Bhopal, Madhya Pradesh, India
- 4. Senior Resident, Department of Pathology, Gandhi Medical College, Bhopal, Madhya Pradesh, India
Description
Background: Cervical cancer is a leading cause of AIDS-defining illness, and HIV-positive women worldwide. Detection of cervical cancer in precancerous stage is 100% curable. Aim: To determine the rate of cervical screening among HIV-positive women and compare the performance of screening tests and assesses factors affecting participation. Methods: HIV-positive women aged 30–59 years attend the anti-retroviral therapy (ART) clinics were screened by conventional Pap, HPV testing (Hybrid Capture 2) and visual inspection with acetic acid (VIA). A cohort of HIV-negative women from the community matched for age and parity were screened similarly. Screen-positive women underwent colposcopy and biopsy. Factors affecting participation were assessed. Results: Out of total cases majority of them (44.4%) belonged to 30-39 years age group. Most of the participants (96.8%) were unaware about cervical screening, 97.2% were housewives and 74.4% belonged to upper lower socio-economic status. The mean parity of was 2.15±1.29 and maximum (69.2%) females were multiparous. Conventional smear and LBC revealed concordant findings in 16.7%, 100%, 85.7% and 100% cases of ASCUS, LSIL, HSIL and SCC respectively (p<0.05). Among the screening methods, sensitivity and negative predictive value was 100% for detection of abnormal cytology for liquid-based cytology whereas VILI had highest specificity. Overall, diagnostic accuracy was highest for liquid-based cytology. Conclusion: Risk of cervical cancer was higher in HIV infected women. Frequent screening of these patients for cervical cancer can reduces the morbidity and mortality among women.
Abstract (English)
Background: Cervical cancer is a leading cause of AIDS-defining illness, and HIV-positive women worldwide. Detection of cervical cancer in precancerous stage is 100% curable. Aim: To determine the rate of cervical screening among HIV-positive women and compare the performance of screening tests and assesses factors affecting participation. Methods: HIV-positive women aged 30–59 years attend the anti-retroviral therapy (ART) clinics were screened by conventional Pap, HPV testing (Hybrid Capture 2) and visual inspection with acetic acid (VIA). A cohort of HIV-negative women from the community matched for age and parity were screened similarly. Screen-positive women underwent colposcopy and biopsy. Factors affecting participation were assessed. Results: Out of total cases majority of them (44.4%) belonged to 30-39 years age group. Most of the participants (96.8%) were unaware about cervical screening, 97.2% were housewives and 74.4% belonged to upper lower socio-economic status. The mean parity of was 2.15±1.29 and maximum (69.2%) females were multiparous. Conventional smear and LBC revealed concordant findings in 16.7%, 100%, 85.7% and 100% cases of ASCUS, LSIL, HSIL and SCC respectively (p<0.05). Among the screening methods, sensitivity and negative predictive value was 100% for detection of abnormal cytology for liquid-based cytology whereas VILI had highest specificity. Overall, diagnostic accuracy was highest for liquid-based cytology. Conclusion: Risk of cervical cancer was higher in HIV infected women. Frequent screening of these patients for cervical cancer can reduces the morbidity and mortality among women.
Files
IJPCR,Vol16,Issue6,Article6.pdf
Files
(391.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:cc891a500329aa2c049f022768f63727
|
391.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-06-01
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue6,Article6.pdf
- Development Status
- Active
References
- 1. Waymack JR, Sundareshan V. Acquired Immune Deficiency Syndrome. [Updated 2020 Sep 8]. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537 293/ last accessed on 29 July 2021 2. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008 Apr; 118(4):1244-54. 3. Global HIV & AIDS statistics, Fact sheet UNAIDS available from https://www.unaids.org/en/resources/fact-sheet last as accessed on 29 July 2021 4. NACO Events/Updates | National AIDS Control Organization | MoHFW | GoI [Internet]. Available from: http://naco.gov.in/nacoeventsLast accessed on 16th July 2021. 5. Naif HM. Pathogenesis of HIV Infection. Infect Dis Rep. 2013 Jun 6; 5(Suppl 1):e6. 6. Sachan PL, Singh M, Patel ML, Sachan R. A study on cervical cancer screening using pap smear test and clinical correlation. Asia-Pacific journal of oncology nursing. 2018 Jul; 5(3):337. 7. Abila DB, Wasukira SB, Ainembabazi P, Wabinga H. Burden of risk factors for cervicalcancer among women living in East Africa: an analysis of the latest demographic health surveys conducted between 2014 and 2017. JCO Glob Oncol. 2021; 7:1116–28. https:// www.ncbi.nlm.nih.gov/pmc/ articles/PMC845 7811/. 8. Duraisamy K, Jaganathan KS, Bose JC. Methods of detecting cervical cancer. AdvBiol Res., 2011; 5(4):226-32 9. Working Party Report. HIV Infection in Maternity Care and Gynaecology. The Royal College of Obstetricians and Gynaecologists, London, UK. 1997. 10. II. Complementary data on cervical cancer prevention. International Agency for Research on Cancer 2017. Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-07- 27) Available from: https: //hpvcentre. Net/statistics/reports/IND_FS.pdf. [Last accessed on 2018 Jul 25]. 11. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health 2015; 7:405-14. 12. World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO 2013. Available from: http://apps.who.int/ iris/bitstream/handle/10665/94830/978924154 8694_eng. pdf? Sequence=1. [Last accessed on 2018 Jul 06] 13. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bull World Health Organization. 2001; 79:954-62. 14. Solomon D. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. Aca Cytol 1989; 33:567-574 15. Boddu A, Bhatla N, Vashist S, Mathur S, Mahey R, Natarajan J, Malik R, Vanamail P, Rai S, Kumari A, Dar L. Cervical Cancer Screening in HIV-Positive Women in India: Why, When and How? The Journal of Obstetrics and Gynecology of India. 2021 Feb 19:1-9. 16. Kelly HA, Chikandiwa A, Sawadogo B, Gilham C, Michelow P, Lompo OG, Omar T, Zan S, Magooa P, Segondy M, Nagot N. Diagnostic accuracy of cervical cancer screening and screening–triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study. PLoS medicine. 2021 Mar 4; 18(3):e1003528. 17. Naidu NP, Jaju PB. Comparison of Visual Inspection with Acetic Acid and Pap smear in Detecting Premalignant Lesions of Cervix. Int J Sci Stud 2019;6(11):130-6 18. Denning P, DiNenno E. Communities in crisis: is there a generalized HIV epidemic in impoverished urban areas of the United States. In XVIII international AIDS conference 2010 Jul 18 (Vol. 1). 19. Shamsunder S, Pannu D, Khanna G, Banerjee A, Zutshi V, Malik S. Comparison of cervical cancer screening by visual inspection with acetic acid versus cervical-cytology in pregnancy. Indian J Med Paediatr Oncol. 2019; 40:85-9 20. S Shah, H Montgomery, C Smith, Madge, P Walker,3H Evans, M Johnson and C Sabin, Cervical screening in HIV-positive women: characteristics of those who default and attitudes towards screening, HIV Medicine. 2006; 7: 46–52. 21. Nakamura A, Yamaguchi K, Minamiguchi S, Murakami R, Abiko K, Hamanishi J, Kondoh E, Baba T, Mandai M, Matsumura N. Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Medical molecular morphology. 2019 Mar; 52(1):52-9 22. Mokhele I, Evans D, Schnippel K, Swarts A, Smith JS, Firnhaber C. Awareness, perceived risk and practices related to cervical cancer and pap smear screening: a crosssectional study among HIV-positive women attending an urban HIV clinic in Johannesburg, South Africa. South African Medical Journal. 2016; 106(12):1247-53. 23. Korn AK, Muzingwani L, O'Bryan G, EnsmingerA, Boylan AD, Kafidi E-L, et al. (2022) Cervical cancer screening and treatment, HIV infection, and age: Program implementation in seven regions of Namibia. PLoS ONE 17(2): e0263920. 24. Chakravarty J, Chourasia A, Thakur M, Singh AK, Sundar S, Agrawal NR. Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. The Indian journal of medical research. 2016 Jan; 143(1):79. 25. Rahatgaonkar VG, Deshpande AA, Oka GA. Screening for cervical cancer in HIV-infected women: A review of literature. Indian J Cancer 2021; 58:317-25. 26. Najjuka Sarah Maria, Connie Olwit, Mark Mohan Kaggwa, Rose Chalo Nabirye and Tom Denis Ngabirano, Cervical cancer screening among HIV-positive women in urban Uganda: a cross sectional study, BMC Women's Health. 2022; 22:148 27. Bhattacharyya AK, Nath JD, Deka H. Comparative study between pap smear and visual inspection with acetic acid (via) in screening of CIN and early cervical cancer. Journal of midlife health. 2015 Apr; 6(2):53 28. Singh U, Anjum SQ, Negi N, Singh N, Goel M, Srivastava K. Comparative study between liquid-based cytology & conventional Pap smear for cytological follow up of treated patients of cancer cervix. The Indian journal of medical research. 2018 Mar; 147(3):263.29. Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol 2014; 45: 58-74.